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The aim was to investigate the role of rabeprazole on the pharmacokinetics (PK) and pharmacodynamics
(PD) of metformin. The in vitro inhibition assays on metformin transport were carried out and showed
that the half maximal inhibitory concentration (IC50) of rabeprazole on OCT2-mediated metformin
transport was 26.0 mM, whereas the IC50 on MATE1-mediated metformin transport inhibition was 4.6 mM.
Fifteen healthy Chinese male volunteers were enrolled and given two different doses of metformin plus
the co-administration of placebo or rabeprazole. Plasma concentrations of metformin were measured up
to 12 h after the second dose. The glucose-lowering effects and the variation of insulin concentrations
were evaluated during the oral glucose tolerance test (OGTT). The AUC0e12 of metformin plus rabeprazole
were 28,276 ± 5187 ng/ml$h, which was signiﬁcantly higher than AUC0e12 of metformin plus placebo
(24,691 ± 3129 ng/ml$h). Thus, rabeprazole can modestly inﬂuence the PK of metformin, suggesting the
precaution of using the two drugs together. In OGTTs, rabeprazole decreased the values of AUCinsulin and
the maximum insulin concentration. Although rabeprazole showed inhibition effect on OCT2-mediated
metformin transport, the glucose-lowering effect of metformin remained the same regardless of its PK
changes. Further studies are needed to warrant the effect of rabeprazole on metformin.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Metformin is an insulin-sensitizing agent, widely used in the
treatment of type 2 diabetes mellitus (DM), as well as in non-
alcoholic fatty liver disease (NAFLD) (1e4). Metformin down-
regulates blood glucose through increasing the insulin sensitivity in
muscle, improving the efﬁciency of the lactate oxidative and
enhancing the proportion of glucose oxidation (5). Additionally, it
can decrease hepatic glucose output and gluconeogenesis (6). It
was even reported that metformin could be used to treat polycystic
ovary syndrome (PCOS) via the regulation of pituitary gonadotropin
secreting cells (7) and protect against carbon tetrachloride inducedrmacology, Xiangya Hospital,
hangsha, Hunan 410078, PR
476.
rmacological Society.
le.
. Production and hosting by Elsehepatotoxicity (8). During the last decade, increasing evidence have
suggested thatmetformin plays an positive role in cancer treatment
and prevention (9,10).
Metformin is a substrate of organic cation transporters (OCTs)
and multidrug and toxin extrusion 1 (MATE1) transporter, which
localized at liver and gastrointestinal or renal epithelium respon-
sible for drug absorption and excretion (11,12). Metformin does not
undergo metabolism in the liver or other organs and is excreted
unchanged through kidney tubules (13). Renal dysfunction or
drugedrug interactions (DDIs) through the inhibition of OCTs and
MATE1 transporters could cause the accumulation of metformin
and increase the risk of lactic acidosis (14). Based on computational
analysis and high-throughput assay, Y. Kido et al. (15) had discov-
ered a number of drugs, including rabeprazole that have a large
inhibition potency on OCT2. Moreover, Nies et al. (16) found that
rabeprazole might inﬂuence the uptake of metformin by inhibiting
OCT1, OCT2, and OCT3 in a concentration-dependent manner, using
in vitro transporting assay (IC50 ¼ 3.0, 5.7, and 3.0 mM,
respectively).vier B.V. This is an open access article under the CC BY-NC-ND license (http://
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side effects during metformin therapy (17). Rabeprazole was pre-
scribed to treat gastrointestinal diseases, particularly gastro-
esophageal reﬂux. Therefore, co-administration of rabeprazole and
metformin is frequently occurred for diabetic patients. However,
there was no data about the PK and PD variation in Chinese after
co-administration of these two drugs. Here, we recruited 15 Chi-
nese healthy volunteers to illustrate the possible inﬂuence of PK
and PD of metformin after co-administration of rabeprazole, which
would be indicative for doctors to prescribe these two drugs
properly.2. Materials and methods
2.1. Chemicals and reagents
The Flp-In transfection system, Dulbecco's modiﬁed Eagle's
medium (DMEM), Lipofectamine 2000, hygromycin, Opti-MEM
reduced serum medium, TRIzol, and fetal bovine serum were pur-
chased from Invitrogen. The pcDNA5-hOCT2 and -hMATE1 plas-
mids were already constructed in the laboratory of Yan Shun from
University of Maryland. All HEK-293 Flp-In cells stably expressing
these transporters were established by selection against hygrom-
ycin (75 mg/mL) according to the Flp-In transfection system in-
struction (Invitrogen). [14C]-metformin was purchased from
Moravek Biochemicals Inc. (Brea, CA). Rabeprazole and unlabeled
metformin were obtained from Sigma Chemical Co. LLC. (St. Louis,
MO).2.2. In vitro inhibition of metformin transport by rabeprazole
HEK-293 cells stably overexpressing transporters and mock
HEK-293 cells were cultured in DMEM supplementedwith 10% fetal
bovine serum, 100 U/mL penicillin, 100 mg/mL streptomycin, and
75 mg/mL hygromycin, and were maintained in 25-cm2 plastic
ﬂasks at 37 C in a humidiﬁed atmosphere with 5% CO2. Twenty
four hours before the uptake experiments, cells were digested with
trypsin containing 0.25% EDTA and counted. 2  105 Cells were
plated in each well. The protocol of uptake experiment was ac-
cording to the study of Qing Li (18) and brieﬂy indicated as
following. During the experiment of OCT2 inhibition, the cells were
washed once with pre-warmed KRH buffer and then incubated
with KRH buffer containing different concentrations of rabeprazole
with 10 mM [14C]-metformin plus 40 mM unlabeled metformin for
10 min. The uptake was haltered by removing the KRH buffer and
washing the cells with ice-cold KRH buffer for 3 times. For the in-
hibition of MATE1 transport, the cells were ﬁrstly washed with pre-
warmed Kþ based buffer and then incubated in Kþ based buffer
containing 30 mM NH4Cl for 10 min at 37 C, and thereafter incu-
bated in the uptake buffer (NH4Cl-free) for another 5 min. The
culture medium was then changed to the uptake buffer containing
a series of concentrations of inhibitors with 10 mM [14C]-metformin
plus 40 mM unlabeled metformin for 10 min and the assays were
stopped by addition of ice-cold substrate-free uptake buffer, and
the cells were washed 3 times. At last, 300 mL 0.5 N sodium hy-
droxide (NaOH) were added in each well, and thereafter the plate
was shaken for 30 min and added 0.5 N hydrochloric acid (HCL) to
neutralize the buffer. 300 mL cell lysate was transferred to scintil-
lation tube containing 3 mL Biodegradable Counting Cocktail buffer
(Fisher Scientiﬁc Inc., Pittsburgh, PA). Radioactivity was counted by
a multi-purpose scintillation counter (Beckman LS6500 Counter,
Brea, CA). Protein concentrations were measured using a BCA
protein assay kit (Bio-Rad Co. Hercules, CA), which was used for
normalizing radioactivity values.2.3. Subjects
Our study protocol was approved by the Ethics Committee
Institute of Clinical Pharmacology, Central South University (Project
No: CTXY-140012). Fifteen healthy Chinese males were enrolled in
the study, and all of them provided informed written consent
before enrollment. The baseline characteristics of subjects were:
age, 25.3 ± 6.5 years; height, 172.2 ± 4.5 cm; and weight,
76.9 ± 9.7 kg (mean ± SD). Subjects with anemia, abnormal of
hepatic enzyme level, serum creatinine level>1.50 mg/dl, history of
drug abuse, or presentation of any one of the criterias for metabolic
syndrome were excluded from our study. Also excluded were those
consuming more than two drinks a week, smoking more than ten
cigarettes a day, or taking any medication in the past 3 months.
2.4. Clinical study design
This was a randomized, two-crossover studywith a 14-daywash
out period. In each phase, ﬁfteen volunteers randomly received
placebo or rabeprazole (20 mg, 10 mg per tablet) orally from day-1
to day-7 at 8:00 AM to attain the steady state concentration (Misato
Plant of Eisai Co., Ltd, Xiangya Hospital of Central South University,
ChangSha, China) and two doses of metformin (250 mg per tablet;
Neptunus Pharmaceutical. Co., Ltd, Changsha, China). The ﬁrst dose
ofmetformin (1000mg) was taken orally on day-6 at 20:00 PM, and
the second dose (750 mg) metformin together with rabeprazole or
placebo was given on day-7 at 8:00 AMwith a 12 h interval (18,19).
In each period, themeal was supplied by the Clinical Trials Center at
Hunan Cancer Hospital. Two hours after the last dose of metformin,
oral glucose tolerance test (OGTT) was performed following the
injection of 75 g glucose.
2.5. Sample collection
After drug administration, blood samples (5 ml per time point)
for measuring plasma metformin concentrations were collected
immediately before and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0,
10.0, 12.0 h. Blood samples for determining plasma glucose and
insulin concentration were collected immediately before and 0.25,
0.5, 0.75, 1.0, 1.5, 2.0, and 3.0 h after glucose ingestion. After
collection, the blood samples were centrifuged in 3000 rpm for
10 min in 4 C, and all the plasma samples were separated and
frozen at 80 C pending assaying.
2.6. Metformin plasma concentration analysis
Metformin assaying was performed on a Shimadzu LC-2010C
HPLC system (Kyoto, Japan) with autosampler and ultraviolet
detector. Simple protein precipitation was carried out by adding
400 ml acetonitrile with coumarin as internal standard into 200 ml
plasma. The mixture was vortexed for 10 min and centrifuged at
16,000 g for 10 min. An aliquot of the supernatant was trans-
ferred to a vial, and 20 ml of this sample solution was injected into
the HPLC-UV system column (4.60 mm  200 mm, i.d., 5 mm,
Hypersil BDS C18 column) with UV detection at 232 nm. The
mobile phase was composed of 34% acetonitrile and 66% aqueous
phase with the ﬂow rate at 1.00 ml/min. Maximum metformin
concentration (Cmax) and the time of maximum concentration
(Tmax) were determined, and the area under the metformin
plasma concentration curve (AUC) was calculated by the linear
trapezoidal rule. The elimination rate constant (Ke) was estimated
from the slope of the best-ﬁt line determined by linear regression
analysis of the log-transformed concentrationetime curve. The
elimination half-life (t1/2) was calculated from the equation t1/
2 ¼ ln(2)/Ke.
Table 1
Pharmacokinetic parameters of metformin plus placebo or rabeprazole in healthy
subjects (n ¼ 15).
Parameter Metformin
þ placebo
Metformin
þ rabeprazole
p value
AUC0e12 (ng/ml$h) 24,691 ± 3129 28,276 ± 5187 0.001
AUC0-6 (ng/ml$h) 17,855 ± 2445 20,690 ± 3692 0.001
AUC6e12 (ng/ml$h) 6801 ± 1399 7762 ± 1727 0.005
Cmax (ng/ml) 4220 ± 766 5003 ± 1023 0.001
Tmax(h) 1.23 ± 0.45 1.50 ± 0.68 0.164
t1/2(h) 4.56 ± 0.84 4.46 ± 0.94 0.635
The data shown for each parameter are mean ± SD; AUC (aeb), area under the plasma
concentrationetime curve from time point a to time point b.
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Paired Sample T test was used to analyze the PK and PD data of
metformin with placebo or rabeprazole. SPSS v.17.00 (IMB Corp.,
Armonk, NY, USA) software was used here. And all data were mean
values ± standard deviation (SD), p < 0.05. Apparent IC50 values for
inhibition of metformin uptake by rabeprazole were calculated for
each individual experiment by ﬁtting the values to the Hill equation
using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA).
3. Results
3.1. In vitro inhibition of OCT2- or MATE1-mediated metformin
transport
Recently, Nies et al. (16) found that rabeprazole is not the sub-
strate of OCT2 but the inhibitor of OCT2. It was reported that
rabeprazole can inhibit OCT2-mediated metformin transport with
IC50 at 5.7 mM. However, the data from our study showed that the
IC50 value of rabeprazole on OCT2-mediated metformin transport
inhibition was 26.0 mM, whereas the IC50 value on MATE1-
mediated metformin transport inhibition was 4.6 mM (Fig. 1).
3.2. Effects of rabeprazole on the plasma concentration of
metformin
The plasma concentrations of metformin co-administered with
placebo or rabeprazole were showed in Fig. 1, and Table 1 showed
that AUC0e12 of metformin co-administered with rabeprazole
increased by 14.5% (24,690 ± 3129 vs 28,276 ± 5,186, p ¼ 0.001)
compared with placebo (see Fig. 2). The difference in AUC0e6 and
AUC6e12 also had statistical signiﬁcance (AUC0-6 increased by 15.9%,
p¼ 0.001; AUC6e12 increased by 14.1%, p¼ 0.005). The Cmax value of
metformin plus rabeprazole also increased by 18.6%, whereas the
Tmax and T1/2 value were not signiﬁcantly altered.
3.3. Effects of rabeprazole on the glucose-lowering effect of
metformin
The plasma glucose concentrations after metformin adminis-
tration were determined and showed in Fig. 3. The maximum
glucose level (Gmax) and the area under the plasma glucose con-
centrationetime curve (AUCglucose) of metformin plus placebo or
rabeprazole group were characterized using the trapezoidal rule.
However, no signiﬁcant differences were found in Gmax or AUCglu-
cose between placebo and rabeprazole group (Table 2).Fig. 1. Inhibition of metformin uptake by rabeprazole. A. HEK-293 Flp-In cells stably express
with 10 mM [14C]-metformin for 10 min at 37 C in the presence of various concentrations o
experiment in several separate experiments.3.4. The effect of rabeprazole on metformin in lowering insulin
concentration
Insulin concentration in peripheral blood was detected and
showed in Fig. 4. The maximum insulin concentration (INmax) and
the area under the serum insulin concentrationetime curve
(AUCinsulin) were also characterized. Compared with the group of
metformin plus placebo, rabeprazole can signiﬁcantly decrease the
value of both INmax and AUCinsulin by 20.4% (Table 2).
4. Discussion
In the past decade, the understanding of the role of drug
transporters on PK gives us more insights on the causes of
drugedrug interactions. Besides, pharmacogenomics study of drug
transporter elucidate that gene mutations also play a role in drug
PK and PD. The longer-term use of metformin will cause several
adverse reactions, such as ketoacidosis and lactic acidosis (19). The
drug interaction on metformin elimination would increase its
systemic exposure level, which might further increase the risk of
these adverse reactions. In another aspect, the co-administration of
drugs, that inhibit its intestinal absorption or the uptake of met-
formin in its targeted organs, will have inﬂuence on its glucose-
lowering effects.
Drug transporters, plasma membrane monoamine transporter
(PMAT), OCTs and MATE1/2k mediates the uptake or efﬂux of
metformin (14). Recent pharmacogenomic studies have revealed
that genetic polymorphisms of MATE1, MATE2K and OCT1-3 are
associated with the glucose-lowering effect or PK of metformin
(20e22). Moreover, clinical studies in healthy population showed
that co-administration of OCTs inhibitors can impact PK and PD of
metformin (23,24).ing hOCT2. B. HEK-293 Flp-In cells stably expressing hMATE1. The cells were incubated
f metformin. Each point represents the mean ± SD of three monolayers from a typical
Fig. 2. Plasma concentrationetime curves of metformin after co-administered with
placebo or rabeprazole in healthy males (n ¼ 15). Plasma metformin concentrations
were determined after the administration of the second dose of metformin. Each value
is the mean value ± standard deviation (SD).
Fig. 3. Serum glucose concentrations in oral glucose tolerance tests were determined
before and after the administration of metformin plus placebo or rabeprazole in
healthy males (n ¼ 15). Each value was the mean value ± SD.
Fig. 4. Serum insulin concentrations in oral glucose tolerance tests were measured
after the administration of metformin plus placebo or rabeprazole in healthy males
(n ¼ 15). Each value was the mean value ± SD.
Table 2
The glucose-lowering and insulin-lowering effect of metformin plus placebo or
rabeprazole in healthy subjects (n ¼ 15).
Parameter Metformin
þ placebo
Metformin
þ rabeprazole
p value
AUCglu(0e3) (mmol/L$h) 16.86 ± 2.08 17.19 ± 2.83 0.506
Cmaxglu (mmol/L) 7.21 ± 1.13 7.26 ± 1.01 0.824
AUCinsulin(0e3) (mIU/mL$h) 148.2 ± 99.5 117.9 ± 68.4 0.013
Cmaxinsulin (mIU/mL) 86.8 ± 44.5 69.1 ± 32.9 0.002
The data shown for each parameter are mean ± SD.
G. Liu et al. / Journal of Pharmacological Sciences 132 (2016) 244e248 247In our study, the co-administration of rabeprazole increased the
Cmax of metformin by 18.6% and AUC by 14.5%. After analyzing the
individual PK of metformin, it was found that three out of 15 sub-
jects have the AUC0e12 change exceed the range of 80e125% which
indicates clinically signiﬁcance, with the highest ratio of 143%.
Likely other PPIs, rabeprazole can strongly inhibit the transporting
ability of OCTs (16). In our study, it was found that rabeprazole can
also strongly inhibit MATE1-mediated metformin transport in vitro
(IC50 ¼ 4.6 mM). OCT2 and MATE1 are abundantly expressed on the
basal and apical layer of renal tubules, respectively, responsible for
the excretion of metformin from plasma to urine. The change of
metformin PKmay be attributed to the inhibition of its excretion by
rabeprazole.
However, the role of rabeprazole on metformin may be more
complicated thanwe have speculated. Firstly, alkaline environment
in gastry may facilitate the dissolving of metformin hydrochloride
tablets and its absorption (25). Rabeprazole can increase gastric pH
and hence facilitates the intestinal absorption of metformin. As
both OCT3 and PMAT were localized on the apical membrane of
human intestine, the co-administration of rabeprazole would
impede the metformin transporting in intestine via the inhibitionof these transporters. Moreover, OCT1 was distributed on the basal
membrane of heptocytes andmay contribute to the translocation of
metformin into heptocytes. It is possible that rabeprazole can
reduce the accumulation of metformin in liver and inﬂuence the
effects of its glucose-lowering.
In our study, although the PK of metformin was changed by
rabeprazole, there was no alteration in the glucose-lowering ef-
fects of metformin between the groups co-administrated with
placebo and rabeprazole. The similar results in OGTTs were also
found in healthy subjects co-administrated with lansoprazole (24).
In human body, especially the healthy individuals, the control of
blood glucose concentration is an extremely complex process on
which the inﬂuence of metformin is slender. However, it was
interesting to ﬁnd in our study that the plasma insulin concen-
trations during OGTTs were signiﬁcantly lower in subjects treated
placebo than rabeprazole. To our knowledge, metformin alone can
enhance the sensitivity of insulin and thereafter the insulin
decreased through the feedback regulation of glucose decline.
This is an early PK study of metformin in 9 healthy subjects and 9
T2DM patients (26). After the single- and multi-dose of metformin,
the postprandial insulin levels of the both groups were signiﬁ-
cantly deregulated compared to placebo control. Also in an animal
study of the drug interaction between clozapine and metformin, it
was found that the mean insulin level in the clozapine plus met-
formin group was signiﬁcantly lower than the levels in the cloza-
pine and saline groups (1.54 vs 2.33 vs 2.55 mIU/mL) (27). Probably
because of the raise of plasma concentration of metformin during
the combined use of rabeprazole and the enhanced glucose-
lowering effect of insulin, insulin levels, thereafter, decreased
through feedback regulation when rabeprazole was co-
administrated. Also, this is a conjecture that rabeprazole may
decrease the secretion of insulin, which need to be proved by the
investigation of rabeprazole and metformin on plasma insulin in
both healthy and diabetic populations.
G. Liu et al. / Journal of Pharmacological Sciences 132 (2016) 244e248248There are also some limitations in our study. Firstly our study
was only performed in healthy Chinese volunteers, whereas Sam-
bol et al. (26) certiﬁed that the metformin PK-PD relationship had
altered a lot in patients with type 2 DM by comparing with healthy
subjects. Therefore, the study should be repeated in patients with
type 2 DM. Furthermore, the urine samples from subjects after drug
dosing were not collected. The urine clearance of metformin in
placebo and rabeprazole co-administrated groups cannot be
compared. As both metformin and rabeprazole are orally admin-
istrated, it is necessary to further investigate whether rabeprazole
can inhibit the PMAT-mediated metformin transport.
In summary, the combination of rabeprazole changed the
pharmacokinetic feature of metformin, probably because of its in-
hibition on the renal metformin excretion. Although there was no
obvious difference on the change of blood glucose levels between
metformin plus placebo and rabeprazole during the OGTT tests, the
levels of insulin was much lower in subjects treated with metfor-
min plus rabeprazole. However, more investigations are needed to
reveal the underlying mechanism of rabeprazole on insulin
excretion.
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